| Gender Preference | None |
| Age Group | 18 - 99 years |
| Research Start Date | August 29, 2012 |
| Research End Date | August 22, 2022 |
| Principal Investigator | Mohammed Milhem, MD |
| Description | Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
Participants in this research study have been diagnosed with multiple myeloma. This study is being done to see if the investigational drug (tabalumab) is safe and how well it works to help people with this particular cancer. Researchers also want to investigate how much tabalumab should be given and if tabalumab in combinsation with the drugs bortezomib and dexamethasone help people with myeloma. Researchers also want to investigate if the combination of drugs is safe and what side effects are associated with them. |
| Contact Info | Melanie Frees, 319-356-1228 |
| Keywords | span itemProp='description'>Alkylating Agents ; Antineoplastic Agents ; Bortezomib ; Cancer ; Connective and Soft Tissue ; Dexamethasone ; IRB#201205703 ; Metastatic Soft Tissue Sarcoma ; Milhem ; Multiple Myeloma ; Neoplasms ; Phase 3 ; Phase III ; Refractory to Standard of Care Treatment ; Relapsed ; YONDELIS (trabectedin) ; |